Registration Statement for Securities to Be Issued in Business Combination Transactions (s-4/a)
2020年4月7日 - 6:18AM
Edgar (US Regulatory)
As
filed with the Securities and Exchange Commission on April 6, 2020
Registration
No. 333-236235
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
AMENDMENT
NO. 4 TO
FORM
S-4
REGISTRATION
STATEMENT
UNDER
THE SECURITIES ACT OF 1933
RITTER
PHARMACEUTICALS, INC.
(Exact name of Registrant as specified in its charter)
Delaware
|
|
2834
|
|
26-3474527
|
(State
or other jurisdiction of
incorporation or organization)
|
|
(Primary
Standard Industrial
Classification Code Number)
|
|
(I.R.S.
Employer
Identification Number)
|
1880
Century Park East, Suite 1000
Los
Angeles, CA 90067
(310)
203-1000
(Address including zip code, and telephone number, including area code, of Registrant’s principal executive offices)
Andrew
J. Ritter
Chief
Executive Officer
Ritter
Pharmaceuticals, Inc.
1880
Century Park East, Suite 1000
Los
Angeles, CA 90067
(310)
203-1000
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copies
to:
Michael
Sanders
Jennifer
W. Cheng
Wendy
Grasso
Reed
Smith LLP
1901
Avenue of the Stars, Suite 700
Los
Angeles, California 90067-6078
(310)
734-5200
|
|
Michael
Poirier
Qualigen,
Inc.
2042
Corte Del Nogal
Carlsbad,
CA 92011
(760)
918-9165
|
|
Hayden
Trubitt
Stradling
Yocca Carlson & Rauth, a Professional Corporation
4365
Executive Drive, Suite 1500
San
Diego, CA 92121
(858)
926-3000
|
Approximate
date of commencement of proposed sale of the securities to the public:
As soon as practicable after the effectiveness of this registration statement and the satisfaction or waiver of all other conditions
under the Merger Agreement, as amended, as described herein.
If
the securities being registered on this Form are being offered in connection with the formation of a holding company and there
is compliance with General Instruction G, please check the following box. [ ]
If
this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the
following box and list the Securities Act registration statement number of the earlier effective registration statement for the
same offering. [ ]
If
this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list
the Securities Act registration statement number of the earlier effective registration statement for the same offering. [ ]
Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting
company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”
“smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large
accelerated filer [ ]
|
Accelerated
filer [ ]
|
Non-accelerated
filer [X]
|
Smaller
reporting company [X]
|
|
|
|
Emerging
growth company [X]
|
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.
[ ]
If
applicable, place an X in the box to designate the appropriate rule provision relied upon in conducting this transaction:
Exchange
Act Rule 13(e)-4(i) (Cross-Border Issuer Tender Offer) [ ]
Exchange
Act Rule 14d-1(d) (Cross-Border Third-Party Tender Offer) [ ]
The
Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until
the Registrant shall file a further amendment that specifically states that this registration statement shall thereafter become
effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the registration statement shall
become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.
EXPLANATORY
NOTE
Ritter Pharmaceuticals, Inc. (the “Registrant”)
has prepared this Amendment No. 4 to the Registration Statement (the “Registration Statement”) on Form S-4 (File No.
333-236235) solely for the purpose of filing an updated consent of the Registrant’s independent registered public accounting
firm as set forth in Exhibit 23.1 to this Amendment No. 4 to correct a typographical error that was included in Exhibit
23.1 to Amendment No. 3 to the Registration Statement on Form S-4. There are no other changes to Part I or Part II of Amendment
No. 3 to the Registration Statement on Form S-4 filed by the Registrant on the date hereof.
PART
II
INFORMATION
NOT REQUIRED IN JOINT PROXY AND CONSENT SOLICITATION STATEMENT/PROSPECTUS
Item
15. Indemnification of Officers and Directors
The
Ritter Certificate of Incorporation provides that Ritter will indemnify, to the fullest extent authorized by the General Corporation
Law of the State of Delaware (the “DGCL”), each person who is involved in any litigation or other proceeding because
such person is or was a director or officer of Ritter or is or was serving as an officer or director of another entity at Ritter’s
request, against all expense, loss or liability reasonably incurred or suffered in connection therewith. The Ritter Certificate
of Incorporation provides that the right to indemnification includes the right to be paid expenses incurred in defending any proceeding
in advance of its final disposition, provided, however, that such advance payment will only be made upon delivery to Ritter of
an undertaking, by or on behalf of the director or officer, to repay all amounts so advanced if it is ultimately determined that
such director is not entitled to indemnification. If Ritter does not pay a proper claim for indemnification in full within 30
days after Ritter receives a written claim for such indemnification, the Ritter Certificate of Incorporation and the Ritter Bylaws
authorize the claimant to bring an action against Ritter and prescribe what constitutes a defense to such action.
Section
145 of the DGCL permits a corporation to indemnify any director or officer of the corporation against expenses (including attorney’s
fees), judgments, fines and amounts paid in settlement actually and reasonably incurred in connection with any action, suit or
proceeding brought by reason of the fact that such person is or was a director or officer of the corporation, if such person acted
in good faith and in a manner that he reasonably believed to be in, or not opposed to, the best interests of the corporation,
and, with respect to any criminal action or proceeding, if he or she had no reason to believe his or her conduct was unlawful.
In a derivative action, (i.e., one brought by or on behalf of the corporation), indemnification may be provided only for expenses
actually and reasonably incurred by any director or officer in connection with the defense or settlement of such an action or
suit if such person acted in good faith and in a manner that he or she reasonably believed to be in, or not opposed to, the best
interests of the corporation, except that no indemnification will be provided if such person has not been adjudged to be liable
to the corporation, unless and only to the extent that the court in which the action or suit was brought determines that the defendant
is fairly and reasonably entitled to indemnity for such expenses despite such adjudication of liability.
Pursuant
to Section 102(b)(7) of the DGCL, the Ritter Certificate of Incorporation eliminates the liability of a director to Ritter or
the Ritter Stockholders for monetary damages for a breach of fiduciary duty as a director, except for liabilities arising:
|
●
|
from
any breach of the director’s duty of loyalty to Ritter or the Ritter Stockholders;
|
|
|
|
|
●
|
from
acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law;
|
|
|
|
|
●
|
under
Section 174 of the DGCL; or
|
|
|
|
|
●
|
from
any transaction from which the director derived an improper personal benefit.
|
Ritter
carries insurance policies insuring its directors and officers against certain liabilities that they may incur in their capacity
as directors and officers.
In
addition, Ritter has entered into indemnification agreements with each of its current directors and executive officers. These
agreements require Ritter to indemnify these individuals to the fullest extent permitted under Delaware law against liabilities
that may arise by reason of their service to Ritter and to advance expenses incurred as a result of any proceeding against them
as to which they could be indemnified. Ritter also intends to enter into indemnification agreements with its future directors
and executive officers.
Item
16. Exhibits
A
list of exhibits filed with this registration statement on Form S-4 is set forth on the Exhibit Index and is incorporated herein
by reference.
The
financial statements filed with this registration statement on Form S-4 are set forth on the Financial Statement Index and are
incorporated herein by reference.
Item
17. Undertakings
|
(a)
|
The
undersigned registrant undertakes as follows:
|
|
(1)
|
that
prior to any public reoffering of the securities registered hereunder through use of a prospectus which is a part of this
registration statement, by any person or party who is deemed to be an underwriter within the meaning of Rule 145(c), the issuer
undertakes that such reoffering prospectus will contain the information called for by the applicable registration form with
respect to reofferings by persons who may be deemed underwriters, in addition to the information called for by the other items
of the applicable form.
|
|
|
|
|
(2)
|
that
every prospectus (i) that is filed pursuant to paragraph (1) immediately preceding, or (ii) that purports to meet the requirements
of Section 10(a)(3) of the Securities Act of 1933 and is used in connection with an offering of securities subject to Rule
415, will be filed as a part of an amendment to the registration statement and will not be used until such amendment is effective,
and that, for purposes of determining any liability under the Securities Act of 1933, each such post-effective amendment shall
be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities
at that time shall be deemed to be the initial bona fide offering thereof.
|
|
|
|
|
(3)
|
to
respond to requests for information that is incorporated by reference into this joint proxy and consent solicitation statement/prospectus
pursuant to Item 4, 10(b), 11, or 13 of Form S-4, within one business day of receipt of such request, and to send the incorporated
documents by first class mail or other equally prompt means. This includes information contained in documents filed subsequent
to the effective date of the registration statement through the date of responding to the request.
|
|
|
|
|
(4)
|
to
supply by means of a post-effective amendment all information concerning a transaction, and the company being acquired involved
therein, that was not the subject of and included in the registration statement when it became effective.
|
|
(b)
|
Insofar
as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling
persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the
opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities
Act of 1933 and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other
than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant
in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in
connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has
been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification
by it is against public policy as expressed in the Securities Act of 1933 and will be governed by the final adjudication of
such issue.
|
INDEX
TO EXHIBITS
|
|
|
|
Incorporated
by Reference
|
Exhibit
No.
|
|
Description
|
|
Form
|
|
File
No.
|
|
Exhibit
|
|
Filing
Date
|
|
|
|
|
|
|
|
|
|
|
|
2.1^
|
|
Agreement and Plan of Merger, by and among Ritter Pharmaceuticals, Inc., RPG28 Merger Sub, Inc. and Qualigen Inc., dated January 15, 2020 (included in Annex A to the joint proxy and consent solicitation statement/prospectus forming a part of this Registration Statement)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2.2^
|
|
Amendment No. 1 to Agreement and Plan of Merger by and among Ritter Pharmaceuticals, Inc., RPG28 Merger Sub, Inc. and Qualigen, Inc., dated February 1, 2020 (included in Annex B to the joint proxy and consent solicitation statement/prospectus forming a part of this Registration Statement)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2.3^
|
|
Amendment No. 2 to Agreement and Plan of Merger by and among Ritter Pharmaceuticals, Inc., RPG28 Merger Sub, Inc. and Qualigen, Inc., dated March 26, 2020 (included in Annex C to the joint proxy and consent solicitation statement/prospectus forming a part of this Registration Statement)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3.1
|
|
Amended
and Restated Certificate of Incorporation of Ritter Pharmaceuticals, Inc.
|
|
8-K
|
|
001-37428
|
|
3.1
|
|
7/1/2015
|
|
|
|
|
|
|
|
|
|
|
|
3.2
|
|
Certificate
of Amendment to the Amended and Restated Certificate of Incorporation
|
|
8-K
|
|
001-37428
|
|
3.1
|
|
9/15/2017
|
|
|
|
|
|
|
|
|
|
|
|
3.3
|
|
Certificate
of Amendment to the Amended and Restated Certificate of Incorporation
|
|
8-K
|
|
001-37428
|
|
3.1
|
|
3/22/2018
|
|
|
|
|
|
|
|
|
|
|
|
3.4
|
|
Amended
and Restated Bylaws of Ritter Pharmaceuticals, Inc.
|
|
8-K
|
|
001-37428
|
|
3.2
|
|
7/1/2015
|
|
|
|
|
|
|
|
|
|
|
|
3.5
|
|
Certificate
of Designation of Series A Convertible Preferred Stock
|
|
8-K
|
|
001-37428
|
|
3.1
|
|
10/4/2017
|
|
|
|
|
|
|
|
|
|
|
|
3.6
|
|
Certificate
of Designation of Series B Convertible Preferred Stock
|
|
10-Q
|
|
001-37428
|
|
3.1
|
|
11/9/2018
|
|
|
|
|
|
|
|
|
|
|
|
3.7
|
|
Certificate
of Designation of Series C Convertible Preferred Stock
|
|
10-Q
|
|
001-37428
|
|
3.2
|
|
11/9/2018
|
|
|
|
|
|
|
|
|
|
|
|
3.8^
|
|
Form of Certificate of Designation of Series Alpha Convertible Preferred Stock
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3.9^
|
|
Form of Certificate of Amendment to the Amended and Restated Certificate of Incorporation for Reverse Stock Split (included in Annex E to the joint proxy and consent solicitation statement/prospectus forming a part of this Registration Statement)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3.10^
|
|
Form of Certificate of Amendment to the Amended and Restated Certificate of Incorporation for Name Change (included in Annex F to the joint proxy and consent solicitation statement/prospectus forming a part of this Registration Statement)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4.1
|
|
Form
of Common Stock Certificate of Ritter Pharmaceuticals, Inc.
|
|
8-K
|
|
001-37428
|
|
4.1
|
|
3/22/2018
|
4.2
|
|
Form
of Common Stock Purchase Warrant
|
|
S-1
|
|
333-208818
|
|
4.7
|
|
12/31/2015
|
|
|
|
|
|
|
|
|
|
|
|
4.3
|
|
Form
of Representative’s Warrant Agreement
|
|
S-1/A
|
|
333-202924
|
|
4.7
|
|
5/8/2015
|
|
|
|
|
|
|
|
|
|
|
|
4.4
|
|
Warrant
Agency Agreement by and between Ritter Pharmaceuticals, Inc. and Corporate Stock Transfer, Inc. and Form of Warrant Certificate
|
|
8-K
|
|
001-37428
|
|
4.1
|
|
10/4/2017
|
|
|
|
|
|
|
|
|
|
|
|
4.5
|
|
First
Amendment to Warrant Agency Agreement by and between Ritter Pharmaceuticals, Inc. and Corporate Stock Transfer, Inc.
|
|
8-K
|
|
001-37428
|
|
4.1
|
|
5/7/2018
|
|
|
|
|
|
|
|
|
|
|
|
4.6
|
|
Registration
Rights Agreement, by and among Ritter Pharmaceuticals, Inc. and the Purchasers signatory thereto, dated October 30, 2018
|
|
10-Q
|
|
001-37428
|
|
10.5
|
|
11/9/2018
|
|
|
|
|
|
|
|
|
|
|
|
4.7
|
|
Amended
and Restated Registration Rights Agreement, by and between Ritter Pharmaceuticals, Inc. and Aspire Capital Fund LLC, dated
July 23, 2019
|
|
8-K
|
|
001-37428
|
|
4.1
|
|
7/24/2019
|
|
|
|
|
|
|
|
|
|
|
|
4.8^
|
|
Description of Common Stock
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5.1^
|
|
Legal Opinion of Reed Smith LLP
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
8.1^
|
|
Legal Opinion of Reed Smith LLP
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
8.2^
|
|
Legal Opinion of Stradling Yocca Carlson & Rauth, a Professional Corporation
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.1
|
|
Offer
Letter, dated December 2, 2014, by and between Michael D. Step and Ritter Pharmaceuticals, Inc.
|
|
S-1
|
|
333-202924
|
|
10.2
|
|
5/8/2015
|
|
|
|
|
|
|
|
|
|
|
|
10.2+
|
|
Executive
Compensation Plan
|
|
S-1
|
|
333-202924
|
|
10.3
|
|
5/8/2015
|
|
|
|
|
|
|
|
|
|
|
|
10.3+
|
|
2015
Equity Incentive Plan
|
|
S-8
|
|
333-207709
|
|
99.3
|
|
10/30/15
|
|
|
|
|
|
|
|
|
|
|
|
10.4+
|
|
Amendment
to 2015 Equity Incentive Plan
|
|
8-K
|
|
001-37428
|
|
10.1
|
|
6/6/2016
|
|
|
|
|
|
|
|
|
|
|
|
10.5+
|
|
Second
Amendment to 2015 Equity Incentive Plan
|
|
8-K
|
|
001-37428
|
|
10.1
|
|
6/6/2017
|
|
|
|
|
|
|
|
|
|
|
|
10.6+
|
|
Third
Amendment to 2015 Equity Incentive Plan
|
|
8-K
|
|
001-37428
|
|
10.1
|
|
9/15/2017
|
|
|
|
|
|
|
|
|
|
|
|
10.7+
|
|
Form
of Notice of Grant of Stock Option under the 2015 Equity Incentive Plan
|
|
S-8
|
|
333-207709
|
|
99.4
|
|
10/30/15
|
|
|
|
|
|
|
|
|
|
|
|
10.8+
|
|
Form
of Performance Restricted Stock Unit Award Agreement
|
|
10-K
|
|
001-37428
|
|
10.10
|
|
4/1/2019
|
|
|
|
|
|
|
|
|
|
|
|
10.9+
|
|
Stock
Option Agreement, dated September 25, 2013, by and between Ritter Pharmaceuticals, Inc. and Andrew J. Ritter
|
|
S-1
|
|
333-202924
|
|
10.11
|
|
5/8/2015
|
|
|
|
|
|
|
|
|
|
|
|
10.10+
|
|
Stock
Option Agreement, dated December 2, 2014, by and between Ritter Pharmaceuticals, Inc. and Andrew J. Ritter
|
|
S-1
|
|
333-202924
|
|
10.12
|
|
5/8/2015
|
|
|
|
|
|
|
|
|
|
|
|
10.11+
|
|
Stock
Option Agreement, dated December 2, 2014, by and between Ritter Pharmaceuticals, Inc. and Andrew J. Ritter
|
|
S-1
|
|
333-202924
|
|
10.13
|
|
5/8/2015
|
|
|
|
|
|
|
|
|
|
|
|
10.12+
|
|
Stock
Option Agreement, dated September 25, 2013, by and between Ritter Pharmaceuticals, Inc. and Ira E. Ritter
|
|
S-1
|
|
333-202924
|
|
10.14
|
|
5/8/2015
|
10.13+
|
|
Stock
Option Agreement, dated December 2, 2014, by and between Ritter Pharmaceuticals, Inc. and Ira E. Ritter
|
|
S-1
|
|
333-202924
|
|
10.15
|
|
5/8/2015
|
|
|
|
|
|
|
|
|
|
|
|
10.14+
|
|
Stock
Option Agreement, dated December 2, 2014, by and between Ritter Pharmaceuticals, Inc. and Ira E. Ritter
|
|
S-1
|
|
333-202924
|
|
10.16
|
|
5/8/2015
|
|
|
|
|
|
|
|
|
|
|
|
10.15
|
|
Research
and Development Agreement & License, dated November 30, 2010, by and among Kolu Pohaku Technologies, LLC, Kolu Pohaku
Management, LLC and Ritter Pharmaceuticals, Inc.
|
|
S-1
|
|
333-202924
|
|
10.17
|
|
5/8/2015
|
|
|
|
|
|
|
|
|
|
|
|
10.16
|
|
Amendment
No. 1 to Research and Development Agreement & License, dated July 6, 2011, by and among Kolu Pohaku Technologies, LLC,
Kolu Pohaku Management, LLC and Ritter Pharmaceuticals, Inc.
|
|
S-1
|
|
333-202924
|
|
10.18
|
|
5/8/2015
|
|
|
|
|
|
|
|
|
|
|
|
10.17
|
|
Amendment
No. 2 to Research and Development Agreement & License, dated September 30, 2011, by and among Kolu Pohaku Technologies,
LLC, Kolu Pohaku Management, LLC and Ritter Pharmaceuticals, Inc.
|
|
S-1
|
|
333-202924
|
|
10.19
|
|
5/8/2015
|
|
|
|
|
|
|
|
|
|
|
|
10.18
|
|
Amendment
No. 3 to Research and Development Agreement & License, dated February 6, 2012, by and among Kolu Pohaku Technologies,
LLC, Kolu Pohaku Management, LLC and Ritter Pharmaceuticals, Inc.
|
|
S-1
|
|
333-202924
|
|
10.20
|
|
5/8/2015
|
|
|
|
|
|
|
|
|
|
|
|
10.19
|
|
Amendment
No. 4 to Research and Development Agreement & License, dated November 4, 2013, by and among Kolu Pohaku Technologies,
LLC, Kolu Pohaku Management, LLC and Ritter Pharmaceuticals, Inc.
|
|
S-1
|
|
333-202924
|
|
10.21
|
|
5/8/2015
|
|
|
|
|
|
|
|
|
|
|
|
10.20
|
|
Put
and Call Option Agreement, dated November 30, 2010, by and between Kolu Pohaku Technologies, LLC and Ritter Pharmaceuticals,
Inc.
|
|
S-1
|
|
333-202924
|
|
10.22
|
|
5/8/2015
|
|
|
|
|
|
|
|
|
|
|
|
10.21+
|
|
Form
of Indemnification Agreement between Ritter Pharmaceuticals, Inc. and each of its directors and executive officers
|
|
S-1/A
|
|
333-202924
|
|
10.29
|
|
4/24/2015
|
|
|
|
|
|
|
|
|
|
|
|
10.22
|
|
Clinical
Supply and Operation Agreement, dated December 16, 2009, by and among Ritter Pharmaceuticals, Inc. and Ricerche Sperimentali
Montale SpA and Inalco SpA
|
|
S-1/A
|
|
333-202924
|
|
10.30
|
|
4/24/2015
|
|
|
|
|
|
|
|
|
|
|
|
10.23
|
|
Amendment
1 to the Clinical Supply and Cooperation Agreement, dated September 25, 2010, by and among Ritter Pharmaceuticals, Inc. and
Ricerche Sperimentali Montale SpA and Inalco SpA
|
|
S-1/A
|
|
333-202924
|
|
10.31
|
|
4/24/2015
|
|
|
|
|
|
|
|
|
|
|
|
10.24+
|
|
Amended
and Restated Offer Letter, by and between Ritter Pharmaceuticals, Inc. and Andrew J. Ritter
|
|
10-Q
|
|
001-37428
|
|
10.5
|
|
8/14/2018
|
|
|
|
|
|
|
|
|
|
|
|
10.25+
|
|
Offer
Letter, by and between Ritter Pharmaceuticals, Inc. and Ira E. Ritter
|
|
10-Q
|
|
001-37428
|
|
10.2
|
|
8/12/2015
|
|
|
|
|
|
|
|
|
|
|
|
10.26+
|
|
Executive
Severance & Change in Control Agreement, by and between Ritter Pharmaceuticals, Inc. and Andrew J. Ritter
|
|
10-Q
|
|
001-37428
|
|
10.3
|
|
8/12/2015
|
|
|
|
|
|
|
|
|
|
|
|
10.27+
|
|
Executive
Severance & Change in Control Agreement, by and between Ritter Pharmaceuticals, Inc. and Ira E. Ritter
|
|
10-Q
|
|
001-37428
|
|
10.4
|
|
8/12/2015
|
10.28
|
|
Lease
Agreement, dated July 9, 2015, between the Company and Century Park
|
|
10-Q
|
|
001-37428
|
|
10.1
|
|
11/10/2015
|
|
|
|
|
|
|
|
|
|
|
|
10.29
|
|
Amendment
No. 2 to Clinical Supply and Cooperation Agreement, effective July 24, 2015, between Ritter Pharmaceuticals, Inc., Ricerche
Sperimentali Montale SpA, and Inalco SpA
|
|
10-Q
|
|
001-37428
|
|
10.2
|
|
11/10/2015
|
|
|
|
|
|
|
|
|
|
|
|
10.30+
|
|
Letter
of Agreement, dated October 20, 2015 between Ritter Pharmaceuticals, Inc. and Chord Advisors, LLC
|
|
10-Q
|
|
001-37428
|
|
10.4
|
|
11/10/2015
|
|
|
|
|
|
|
|
|
|
|
|
10.31
|
|
Amended
and Restated Master Services Agreement, dated May 1, 2018, by and between Ritter Pharmaceuticals, Inc. and Medpace, Inc.
|
|
8-K
|
|
001-37428
|
|
10.1
|
|
5/7/2018
|
|
|
|
|
|
|
|
|
|
|
|
10.32+
|
|
Offer
Letter with John W. Beck, dated May 23, 2018
|
|
8-K
|
|
001-37428
|
|
10.1
|
|
5/29/2018
|
|
|
|
|
|
|
|
|
|
|
|
10.33
|
|
Executive
Severance and Change in Control Agreement, by and between Ritter Pharmaceuticals, Inc. and John W. Beck, effective May 24,
2018
|
|
8-K
|
|
001-37428
|
|
10.2
|
|
5/29/2018
|
|
|
|
|
|
|
|
|
|
|
|
10.34
|
|
Securities
Purchase Agreement, by and among Ritter Pharmaceuticals, Inc. and the Purchasers signatory thereto, dated October 30, 2018
|
|
10-Q
|
|
001-37428
|
|
10.3
|
|
11/9/2018
|
|
|
|
|
|
|
|
|
|
|
|
10.35
|
|
Form
of Common Stock Purchase Warrant
|
|
10-Q
|
|
001-37428
|
|
10.4
|
|
11/9/2018
|
|
|
|
|
|
|
|
|
|
|
|
10.36
|
|
Placement
Agency Agreement, by and between Ritter Pharmaceuticals, Inc. and A.G.P./Alliance Global Partners, dated October 30, 2018
|
|
10-Q
|
|
001-37428
|
|
10.6
|
|
11/9/2018
|
|
|
|
|
|
|
|
|
|
|
|
10.37
|
|
Amended
and Restated Common Stock Purchase Agreement, by and between Ritter Pharmaceuticals, Inc. and Aspire Capital Fund, LLC, dated
July 23, 2019
|
|
8-K
|
|
001-37428
|
|
10.1
|
|
7/24/2019
|
|
|
|
|
|
|
|
|
|
|
|
10.38+
|
|
Amendment
to Employment Salary Terms, by and between Ritter Pharmaceuticals, Inc. and Andrew Ritter dated October 15, 2019
|
|
8-K
|
|
001-37428
|
|
10.1
|
|
10/15/2019
|
|
|
|
|
|
|
|
|
|
|
|
10.39+
|
|
Amendment
to Employment Salary Terms, by and between Ritter Pharmaceuticals, Inc. and John Beck, dated October 15, 2019
|
|
8-K
|
|
001-37428
|
|
10.2
|
|
10/15/2019
|
|
|
|
|
|
|
|
|
|
|
|
10.40+
|
|
Amendment
to Employment Salary Terms, by and between Ritter Pharmaceuticals, Inc. and Ira Ritter, dated October 15, 2019
|
|
8-K
|
|
001-37428
|
|
10.3
|
|
10/15/2019
|
|
|
|
|
|
|
|
|
|
|
|
10.41
|
|
Sales
Agreement, by and between Ritter Pharmaceuticals, Inc. and A.G.P./Alliance Global Partners
|
|
8-K
|
|
001-37428
|
|
10.1
|
|
11/7/2019
|
|
|
|
|
|
|
|
|
|
|
|
10.42
|
|
Form
of Irrevocable Consent and Waiver of Restriction on Dilutive Issuances
|
|
10-Q
|
|
001-37428
|
|
10.5
|
|
11/14/2019
|
|
|
|
|
|
|
|
|
|
|
|
10.43
|
|
Form of Agreement to Exchange Warrants
|
|
8-K
|
|
001-37428
|
|
10.1
|
|
2/21/2020
|
|
|
|
|
|
|
|
|
|
|
|
10.44^
|
|
Form of CVR Agreement, by and among Ritter Pharmaceuticals, Inc., John Beck in his capacity as CVR Holders’ Representative and Andrew Ritter in his capacity as consultant to Ritter Pharmaceuticals, Inc. (included in Annex D to the joint proxy and consent solicitation statement/prospectus forming a part of this Registration Statement)
|
|
|
|
|
|
|
|
|
10.45^
|
|
Form of Ritter 2020 Stock Incentive Plan (included in Annex G to the joint proxy and consent solicitation statement/prospectus forming a part of this Registration Statement)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.46^
|
|
Financing
Commitment Letter, dated January 15, 2020, by and between Qualigen, Inc. and Alpha Capital Anstalt
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.47^
|
|
Amendment to Financing Commitment Letter, dated March 9, 2020, by and between Qualigen, Inc. and Alpha Capital Anstalt
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.48^
|
|
Distribution
and Development Agreement, dated May 1, 2016, by and between Sekisui Diagnostics, LLC and its Affiliates, and Qualigen, Inc.
and its Affiliates
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.49^
|
|
Letter of Intent, dated March 16, 2018, by and between Sekisui Diagnostics, LLC and Qualigen, Inc.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.50^
|
|
Amendment
to Distribution and Development Agreement, dated April 2, 2018, by and between Sekisui Diagnostics, LLC and Qualigen, Inc.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.51^
|
|
Amendment
to Letter of Intent, dated December 6, 2019, by and between Sekisui Diagnostics, LLC and Qualigen, Inc.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.52^
|
|
Exclusive
Agreement, dated as of June 8, 2018, by and between University of Louisville Research Foundation, Inc. and Qualigen, Inc.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.53^
|
|
License
Agreement, dated as of December 17, 2018, by and between Advanced Cancer Therapeutics, LLC and Qualigen, Inc.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.54^
|
|
Amended
and Restated Letter of Intent, dated August 22, 2018, by and between Sekisui Diagnostics, LLC and Qualigen, Inc.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.55^
|
|
Form of Securities Purchase Agreement by and between Qualigen, Inc. and Alpha Capital Anstalt
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
21.1^
|
|
Subsidiaries
of the Registrant
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
23.1*
|
|
Consent of Mayer Hoffman McCann P.C., independent registered public accounting firm
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
23.2^
|
|
Consent of Squar Milner LLP, independent registered public accounting firm
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
23.3^
|
|
Consent of Reed Smith LLP (contained in Exhibit 5.1)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
23.4^
|
|
Consent of Reed Smith LLP (contained in Exhibit 8.1)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
23.5^
|
|
Consent of Stradling Yocca Carlson & Rauth, a Professional Corporation (contained in Exhibit 8.2)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
24.1^
|
|
Power of Attorney (included on signature page)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.1^
|
|
Form of Proxy Card for Ritter special meeting
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.2^
|
|
Form of Written Consent for Qualigen Stockholders
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.3^
|
|
Consent
of Michael S. Poirier to be named as a Director
|
|
|
|
|
|
|
|
|
101.INS^
|
|
XBRL
Instance Document.
|
|
|
|
101.SCH^
|
|
XBRL
Taxonomy Extension Schema Document.
|
|
|
|
101.CAL^
|
|
XBRL
Taxonomy Extension Calculation Linkbase Document.
|
|
|
|
101.DEF^
|
|
XBRL
Taxonomy Extension Definition Linkbase Document.
|
|
|
|
101.LAB^
|
|
XBRL
Taxonomy Extension Label Linkbase Document.
|
|
|
|
101.PRE^
|
|
XBRL
Taxonomy Extension Presentation Linkbase Document.
|
*
Filed herewith
^
Previously filed
^^
To be filed by amendment
+
Indicates management contract or compensatory plan or arrangement.
SIGNATURES
Pursuant
to the requirements of the Securities Act, the registrant has duly caused this registration statement to be signed on its behalf
by the undersigned, thereunto duly authorized in the City of Los Angeles, State of California, on April 6, 2020.
|
RITTER
PHARMACEUTICALS, INC.
|
|
|
|
|
By:
|
/s/
Andrew J. Ritter
|
|
|
Andrew
J. Ritter
|
|
|
Chief
Executive Officer
|
Pursuant
to the requirements of the Securities Act of 1933, this registration statement has been signed below by the following persons
in the capacities and on the dates indicated.
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
/s/
Andrew J. Ritter
|
|
President
and Chief Executive Officer
|
|
April
6, 2020
|
Andrew
J. Ritter
|
|
(Principal
Executive Officer)
|
|
|
|
|
|
|
|
/s/
John W. Beck
|
|
Chief
Financial Officer
|
|
April
6, 2020
|
John
W. Beck
|
|
(Principal
Financial and Accounting Officer)
|
|
|
|
|
|
|
|
*
|
|
Director
|
|
April
6, 2020
|
Ira
E. Ritter
|
|
|
|
|
|
|
|
|
|
*
|
|
Director
|
|
April
6, 2020
|
Noah
Doyle
|
|
|
|
|
|
|
|
|
|
*
|
|
Director
|
|
April
6, 2020
|
Matthew
W. Foehr
|
|
|
|
|
|
|
|
|
|
*
|
|
Director
|
|
April
6, 2020
|
Paul
V. Maier
|
|
|
|
|
|
|
|
|
|
*
|
|
Director
|
|
April
6, 2020
|
William
M. Merino
|
|
|
|
|
|
|
|
|
|
*
By: /s/ Andrew J. Ritter
|
|
|
|
|
Andrew
J. Ritter
|
|
|
|
|
Attorney-in-fact
|
|
|
|
|
Ritter Pharmaceuticals (NASDAQ:RTTR)
過去 株価チャート
から 6 2024 まで 7 2024
Ritter Pharmaceuticals (NASDAQ:RTTR)
過去 株価チャート
から 7 2023 まで 7 2024